title: Subcutaneous infection with Mycobacterium fortuitum after allogeneic bone marrow transplantation.
abstract: Reports of cases of mycobacterial infections after SCT are rare. We report a 30-year-old female with a cutaneous infection of Mycobacterium fortuitum 30 months after allogeneic bone marrow transplantation for acute lymphoblastic leukemia. The patient was successfully treated with surgical debridement followed by oral minocycline and clarithromycin. Mycobacterial infections should be considered in SCT patients with undiagnosed refractory chronic cutaneous infection, and surgical debridement is useful for the diagnosis and treatment of such infections.
authors.affiliation: Second Department of Medicine, Kyoto Prefectural University of Medicine, 465 Kawaramachi-Hirokoji, Kami-gyoku, Kyoto, 602-8566, Japan.
authors.forename: A
authors.initials: A
authors.lastname: Okano
authors.forename: C
authors.initials: C
authors.lastname: Shimazaki
authors.forename: N
authors.initials: N
authors.lastname: Ochiai
authors.forename: M
authors.initials: M
authors.lastname: Hatsuse
authors.forename: R
authors.initials: R
authors.lastname: Takahashi
authors.forename: E
authors.initials: E
authors.lastname: Ashihara
authors.forename: T
authors.initials: T
authors.lastname: Inaba
authors.forename: N
authors.initials: N
authors.lastname: Fujita
authors.forename: Y
authors.initials: Y
authors.lastname: Noda
authors.forename: M
authors.initials: M
authors.lastname: Nakagawa
mesh_terms: D000328:Adult; D016026:Bone Marrow Transplantation / Q000009:adverse effects*; D017291:Clarithromycin / Q000627:therapeutic use; D003131:Combined Modality Therapy; D016572:Cyclosporine / Q000009:adverse effects / Q000627:therapeutic use; D003646:Debridement; D004359:Drug Therapy, Combination / Q000627:therapeutic use; D005260:Female; D006086:Graft vs Host Disease / Q000188:drug therapy / Q000209:etiology; D006801:Humans; D016867:Immunocompromised Host; D007166:Immunosuppressive Agents / Q000009:adverse effects; D008727:Methotrexate / Q000009:adverse effects / Q000627:therapeutic use; D008911:Minocycline / Q000627:therapeutic use; D009165:Mycobacterium Infections, Nontuberculous / Q000188:drug therapy / Q000209:etiology* / Q000382:microbiology / Q000601:surgery; D019907:Mycobacterium fortuitum / Q000302:isolation & purification*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000276:immunology / Q000628:therapy*; D011239:Prednisolone / Q000009:adverse effects / Q000627:therapeutic use; D012074:Remission Induction; D012883:Skin Ulcer / Q000188:drug therapy / Q000209:etiology* / Q000382:microbiology / Q000601:surgery; D016559:Tacrolimus / Q000009:adverse effects / Q000627:therapeutic use; D019172:Transplantation Conditioning / Q000009:adverse effects; D014184:Transplantation, Homologous
chemical_list: D007166:Immunosuppressive Agents; D016572:Cyclosporine; D011239:Prednisolone; D008911:Minocycline; D017291:Clarithromycin; D016559:Tacrolimus; D008727:Methotrexate